ACP and AAFP endorse treating pain from musculoskeletal injuries with topical NSAIDs as first line therapy. Announcement builds on previously established CDC guidance and adds to the growing collection of recommendations for the use of topical pain relievers.
Two prestigious medical societies now recommend that physicians use topical NSAIDs to treat acute pain from non-low back musculoskeletal injuries. In 2010, musculoskeletal injuries accounted for more than 65 million health care visits in 2010. With rising costs of healthcare and the increasing awareness of the dangers of opioids, more doctors are turning to topical NSAIDs to treat the pain resulting from such injuries. Topical NSAIDs are a safe, effective alternative to opioids and internal NSAIDs. Now, their use as a first line treatment for non-low back musculoskeletal injuries is endorsed by two of the largest doctors’ societies in the United States: the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP).
Musculoskeletal injuries like ankle, neck, and knee injuries are common: they account for 15% of all ER visits and four out of five injuries treated in physicians’ offices are musculoskeletal injuries. While these injuries rarely require hospitalization, physicians know they can seriously impact their patient’s lives. “As a physician, these types of injuries and associated pain are common, and we need to address them with the best treatments available for the patient,” said Jacqueline W. Fincher, MD, president, ACP. “Topical NSAIDs should be the first line of treatment.”
The American College of Physicians is the largest medical specialty organization in the United States, while the AAFP is the only medical society devoted solely to primary care. Between the two organizations they represent nearly 300,000 medical professionals. Their membership treats a large majority of the patients in the United States who experience pain. The guidance issued by these organizations is in line with a larger trend of health authorities recommending the consideration of topical pain relievers. The CDC provides similar guidance advising that doctors consider topical pain relievers as first-line pain relief treatment, especially as an alternative to opioids.
Click here to learn about prior guidance from the CDC.
In their guidance published in Annals of Internal Medicine, the ACP and AAFP recommend “that physicians treat acute pain from non-low back musculoskeletal injuries with topical NSAIDs, with or without menthol gel, as first-line therapy.” Here in the United States, methyl salicylate is a topical NSAID indicated for pain relief from musculoskeletal injury.
The ACP and AAFP recommendations are focused on the active ingredients and not recommending any one particular product.
All of the following Salonpas products have methyl salicylate as an active ingredient.
Click on the package to learn more about each product.
Salonpas® Pain Relief Patch LARGEMore info
Salonpas® Pain Relieving Patch LARGEMore info
Salonpas® Pain Relieving PatchMore info
Salonpas® DEEP Relieving GelMore info
Salonpas® JET SPRAY®More info
- Read the full press release from the ACP and AAFP
- Read the guideline published in Annals of Internal Medicine
- Read about prior guidance from the CDC
Learn more about applicable Salonpas products:
- Salonpas® Pain Relief Patch LARGE
- Salonpas® Pain Relieving Patch
- Salonpas® Pain Relieving Patch LARGE
- Salonpas® DEEP Relieving Gel
- Salonpas® JET SPRAY®